Literature DB >> 23687124

Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study.

Toni Grönberg1, Ilpo Nuotio, Marko Nikkinen, Antti Ylitalo, Tuija Vasankari, Juha E K Hartikainen, K E Juhani Airaksinen.   

Abstract

AIMS: To determine the incidence and risk factors of arrhythmic complications after electrical cardioversion of acute atrial fibrillation (AF). METHODS AND
RESULTS: Our retrospective multicentre study collected data from 7660 cardioversions of acute (<48 h) AF in 3143 consecutive patients. Immediate arrhythmic complications were evaluated after 6906 (90.2%) electrical cardioversions performed in 2868 patients. We also assessed the predictors of arrhythmic complications and whether post-cardioversion bradycardia or asystole led to later a permanent pacemaker implantation. Altogether, 63 (0.9%) electrical cardioversions resulted in bradyarrhythmia in 54 patients. Asystole (>5 s) occurred immediately after 51 cardioversions leading to a short resuscitation in seven cases and two patients needed extrinsic pacing after the cardioversion. In nine cases, asystole was followed by bradycardia. Bradycardic ventricular rate (<40 b.p.m.) alone was seen after 12 procedures. No ventricular arrhythmias needing intervention were detected. Old age [odds ratio (OR) 1.1; 95% confidence interval (CI) 1.05-1.10, P < 0.0001], female sex (OR 2.5; 95% CI 1.4-4.8, P = 0.004), and unsuccessful cardioversion (OR 2.2; 95% CI 1.1-4.6, P = 0.03) were the independent predictors of bradycardic complications. Slow ventricular rate, use of digoxin, beta blocker, or antiarrhythmic medication did not increase the risk of bradycardic complications. Pacemaker was implanted in 24 (44.4%) patients after a median delay of 66 days.
CONCLUSION: Bradycardic complications are rare and usually benign after cardioversion of acute AF. They seem to reflect sinus node dysfunction and often result in later implantation of a permanent pacemaker.

Entities:  

Keywords:  Arrhythmic complication; Atrial fibrillation; Bradycardia; Cardioversion

Mesh:

Year:  2013        PMID: 23687124     DOI: 10.1093/europace/eut106

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  10 in total

1.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Authors:  Edward A El-Am; Angela Dispenzieri; Rowlens M Melduni; Naser M Ammash; Roger D White; David O Hodge; Peter A Noseworthy; Grace Lin; Sorin V Pislaru; Alexander C Egbe; Martha Grogan; Vuyisile T Nkomo
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

2.  Optimal timing for cardioversion in patients with atrial fibrillation.

Authors:  Tapio Hellman; Tuomas Kiviniemi; Ilpo Nuotio; Fausto Biancari; Tuija Vasankari; Juha Hartikainen; Mika Lehto; K E Airaksinen
Journal:  Clin Cardiol       Date:  2018-07-23       Impact factor: 2.882

Review 3.  How to Optimize Cardioversion of Atrial Fibrillation.

Authors:  K E Juhani Airaksinen
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

4.  The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature.

Authors:  Sofia Bezati; Maria Velliou; Eftihia Polyzogopoulou; Antonios Boultadakis; John Parissis
Journal:  Eur Heart J Suppl       Date:  2022-06-13       Impact factor: 1.624

Review 5.  Cardioversion in Non-Valvular Atrial Fibrillation.

Authors:  Hermann H Klein; Hans-Joachim Trappe
Journal:  Dtsch Arztebl Int       Date:  2015-12-11       Impact factor: 5.594

6.  Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol.

Authors:  F Daniel Ramirez; Mouhannad M Sadek; Isabelle Boileau; Mark Cleland; Pablo B Nery; Girish M Nair; Calum J Redpath; Martin S Green; Darryl R Davis; Karen Charron; Joshua Henne; Timothy Zakutney; Rob S B Beanlands; Benjamin Hibbert; George A Wells; David H Birnie
Journal:  Europace       Date:  2019-05-01       Impact factor: 5.214

7.  Renal Dysfunction following Direct Current Cardioversion of Atrial Fibrillation: Incidence and Risk Factors.

Authors:  Nicolai Grüner-Hegge; Danesh K Kella; Deepak Padmanabhan; Abhishek J Deshmukh; Ramila Mehta; David Hodge; Rowlens M Melduni; Eddie L Greene; Paul A Friedman
Journal:  Cardiorenal Med       Date:  2020-12-09       Impact factor: 2.041

8.  Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.

Authors:  Gregory N Beatch; Brian Mangal
Journal:  BMC Cardiovasc Disord       Date:  2016-05-28       Impact factor: 2.298

9.  Effectiveness of a simple medication adjustment protocol for optimizing peri-cardioversion rate control: A derivation and validation cohort study.

Authors:  Nelson Lu; Jenny MacGillivray; Jason G Andrade; Andrew D Krahn; Nathaniel M Hawkins; Zachary Laksman; Marc W Deyell; Shanta Chakrabarti; John A Yeung-Lai-Wah; Matthew T Bennett
Journal:  Heart Rhythm O2       Date:  2021-01-12

10.  Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.

Authors:  Dong Geum Shin; Iksung Cho; Bríain ó Hartaigh; Hee-Sun Mun; Hye-Young Lee; Eui Seock Hwang; Jin-Kyu Park; Jae-Sun Uhm; Hui-Nam Pak; Moon-Hyoung Lee; Boyoung Joung
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.